Agilent Technologies A recently received approval from the Food and Drug Administration (FDA) for a cancer diagnostic, named PD-L1 IHC 28-8 pharmDx. The test will be used in cases of urothelial carcinoma (“UC”) and squamous cell carcinoma of the head and neck (“SCCHN”).
This is a new step in the company's efforts to expand in the growing cancer-diagnostic market.
The PDL1 IHC 28-8 pharmDx test has already been approved for melanoma as well as non-squamous, non-small-cell lung cancer (“NSCLC”). Now, it has been approved for UC and SCCHN patients too. The test enables physicians in the United States to identify UC and SCCHN patients, who still have disease progression on or after platinum-based chemotherapy and are most likely to benefit from treatment with Opdivo.
Opdivo is an immunotherapy developed by Bristol-Myers Squibb (BMS). PD-L1 IHC 28-8 pharmDx was developed in collaboration with Opdivo maker, BMS. Currently, this test has a lot more utility than any other PD-L1 assay in the U.S. market.
Agilent's Role in Healthcare
Currently, the healthcare sector is witnessing a revolution. Personalized medicine is taking the center stage as it could provide improved patient care and better manage costs by administering the most appropriate treatment to individuals. It has been found that not all treatments are suitable for those suffering from a specific disease as some require more specialized tests.
The advancements could have far-reaching effects on the entire healthcare system as personalized medicines considerably improve patient care while reducing medical bills.
Agilent has signed several collaborative agreements with pharma and biotech companies including Pfizer PFE, AstraZeneca AZN, Bristol-MyersSquibb, Merck & Co. MRK, Amgen and Eli Lilly to develop diagnostics using both immunohistochemical and genomic-based technologies for the better treatment of cancer.
Agilent is an original equipment manufacturer (“OEM”) of a broad-based portfolio of test and measurement products serving multiple end markets. We remain positive on Agilent's broad-based portfolio and increased focus on segments with higher growth potential. Further, the company continues to introduce high-margin products.
According to a report from marketsandmarkets.com, the worldwide cancer diagnostics market may reach $13.1 billion by 2020 from $7.1 billion by 2015, driven by several technological advancements in diagnostic platforms. Moreover, the market has seen the advent of hybrid imaging instruments with enhanced accuracy, such as PET/CT and SPECT/CT. These advancements have taken the cancer-diagnostics market to new heights.
We believe the new assay will help Agilent to cash in on the fast-growing healthcare cancer-diagnostics segment.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Astrazeneca PLC (AZN) : Free Stock Analysis Report
Pfizer, Inc. (PFE) : Free Stock Analysis Report
Merck & Company, Inc. (MRK) : Free Stock Analysis Report
Agilent Technologies, Inc. (A) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research